|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on August 8, 2002; DOI 10.1182/blood-2002-04-1150.
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
From the Department of Bone Marrow Transplantation,
University Hospital Hamburg-Eppendorf, and Department of Hematology,
A. K. St Georg, Hamburg, Germany; Department of Oncology and
Hematology, University of Jena, Germany; Department of Bone Marrow
Transplantation, DKD-Clinic, Wiesbaden, Germany; Bone Marrow
Transplantation Clinic, Idar-Oberstein, Germany; and Chaim Sheba
Medical Center, Tel Hashomer, Israel.
We investigated the feasibility of unrelated stem cell
transplantation in 21 patients with advanced stage II/III multiple myeloma after a reduced-intensity conditioning regimen consisting of
fludarabine (150 mg/m2), melphalan (100-140 mg/m2), and antithymocyte globulin (ATG; 10 mg/kg on 3 days). The median patient age was 50 years (range, 32-61 years). All patients had received at least one prior autologous
transplantation, in 9 cases as part of an autologous-allogeneic tandem
protocol. No graft failure was observed. At day 40 complete donor
chimerism was detected in all patients. Grade II to IV acute
graft-versus-host disease (GVHD) was seen in 8 patients (38%), and
severe grade III/IV GVHD was observed in 4 patients (19%). Six
patients (37%) developed chronic GVHD, but only 2 patients (12%)
experienced extensive chronic GVHD. The estimated probability of
nonrelapse mortality at day 100 was 10% and at 1 year was 26%. After
allografting, 40% of the patients achieved a complete remission, and
50% achieved a partial remission, resulting in an overall response
rate of 90%. After a median follow-up of 13 months, the 2-year
estimated overall and progression-free survival rates are 74% (95%
CI, 54%-94%) and 53% (95% CI, 29%-87%), respectively. A shorter
progression-free survival was seen in patients who already experienced
relapse to prior autograft (26% versus 86%, P = .04).
Dose-reduced conditioning with pretransplantation ATG followed by
unrelated stem cell transplantation provides durable engraftment and
donor chimerism, reduces substantially the risk of
transplant-related organ toxicity, and induces high remission rates.
(Blood. 2002;100:3919-3924) After allogeneic stem cell transplantation
(SCT) from HLA-identical related donors, 30% to 50% of the
patients with multiple myeloma (MM) had long-term disease-free
survival with well-documented molecular
remissions.1-4 There is a lower relapse rate
in comparison to autologous transplantation, which is probably due to a
proven graft-versus-myeloma effect.5-7 Despite recent
better control of graft-versus-host disease (GVHD) and of infectious
complications, the most limiting factor for allogeneic SCT is still the
high transplant-related mortality rate of 17% to 40%.8,9
Unrelated SCT is increasingly being used in hematologic diseases such
as chronic myelogenous leukemia (CML) with outcomes quite
similar to those of HLA-identical sibling donor
transplantation.10 However, the limited experience
with unrelated SCT following standard conditioning regimens in
patients with MM are discouraging. Recently, the National Marrow Donor
Program (NMDP) reported a day 100 mortality rate of 41% in 71 myeloma
patients who underwent allogeneic unrelated SCT, and the Seattle group
reported a transplant-related mortality rate of 65% in 14 myeloma
patients who received transplants from unrelated or mismatched related
donors.11,12 However, in the latter study 2 of the
surviving patients are disease-free up to 7 years after
transplantation. These results emphasize the urgent need for
strategies to lower transplant-related mortality in patients with MM
after unrelated SCT.
So-called nonmyeloablative regimens based on fludarabine or low-dose
total body irradiation (TBI) demonstrated stable engraftment of
allogeneic stem cells from related donors in patients with hematologic
diseases including MM.13-16 However, in unrelated SCT after a reduced-intensity melphalan/fludarabine conditioning regimen the nonrelapse mortality (NRM) at day 100 was still 53% mainly due to severe GVHD.17 We report the results of a
multicenter phase I/II study investigating the feasibility of a
fludarabine-melphalan dose-reduced intensity regimen followed by
unrelated SCT in patients with advanced MM. To lower the incidence of
severe GVHD, antithymocyte globulin (ATG), which has been used
successfully in unrelated transplantation after standard conditioning
regimens, was incorporated into the conditioning
regimen.17-21
Patient eligibility
Patient characteristics
The median age of the 13 men and 8 women was 50 years (range, 32-61 years). Ten donors were men and 11 were women. The median Treatment plan Treatment consisted of fludarabine 30 mg/m2 by intravenous infusion over 30 minutes on day 7 to 3 and melphalan by
intravenous infusion of 100 mg/m2 on day 2. ATG (rabbit,
Fresenius, Bad Homburg, Germany) was given at a dose of 10 mg/kg over
12 hours on day 3, 2, and 1, followed by allogeneic SCT on day 0. Six patients received fludarabine 30 mg/m2 only from day
5 to 3; 5 patients received melphalan 140 mg/m2.
Because of 2 grade IV acute GVHD, the following patients (n = 4)
received ATG at a dose of 3 × 20 mg/kg. Granulocyte
colony-stimulating factor (G-CSF; 5 µg/kg) was given intravenously
after allogeneic transplantation from day 5 and continued until
sustained neutrophil engraftment. In case of relapse, incomplete
chimerism, or persistent disease on day 120 additional donor lymphocyte
infusions were scheduled with an escalating regimen starting with
1 × 106 CD3+ cells/kg.
Supportive care Prophylaxis for GVHD consisted of cyclosporin A (3 mg/kg, given from day1 to day +100 after transplantation). The dose of cyclosporin A was adjusted to serum levels. Cyclosporin A was tapered
from day 60 and discontinued at day 100 if no signs of GVHD were
observed. Methotrexate (10 mg/m2) was given on days 1, 3, and 6 after transplantation. Two patients received mycophenolate
mofetil (2 × 1 g from day +1 until day +28) instead of short-course
methotrexate. Acute GVHD was treated with high-dose steroids, and
extensive chronic GVHD with cyclosporin A and steroids. All patients
were nursed in single rooms equipped with a high-efficiency particulate
air (HEPA) filter. Antibiotic prophylaxis consisted of ofloxacin or
ciprofloxacin and antifungal prophylaxis of fluconazole and, in case of
prior mycotic infection, of amphotericin B. Acyclovir was given as
herpes prophylaxis from day 1 until day 180. CMV seropositive patients
received CMV prophylaxis with ganciclovir from stable engraftment
onward until day 100. Pneumocystis carinii
prophylaxis consisted of either trimethoprim and sulfamethoxazole on 3 days of the week or of a monthly inhalation with pentamidine.
All blood products were irradiated before infusion and patients with
seronegativity for CMV received only blood products from CMV Weekly monitoring of blood and urine for CMV antigen by polymerase chain reaction (PCR) and short-term cultures of CMV lower matrix protein pp65+ leukocytes were carried out. In case of positivity, ganciclovir treatment was initiated (5 mg/kg body weight intravenously, twice daily) and discontinued after negative test results were obtained. Regimen-related toxicity was graded using the Bearman score.23 The maximum score for each organ system was recorded. Attempts were made to exclude toxicities due to GVHD from the therapy-related toxicity. Study objective The primary objective of the study was to assess engraftment, chimerism, acute GVHD, toxicity, day 100 mortality, and chronic GVHD in patients undergoing unrelated SCT. Engraftment was defined as a leukocyte count of more than 1 × 109/L for 3 consecutive days and an untransfused platelet count above 20 × 109/L. Chimerism analysis was performed by allele-specific multiplex PCR technique. DNA was prepared from 200 µL blood and bone marrow using the QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany) in accordance with the manufacturer's instructions. T cells were obtained using CD2 MicroBeads and miniMACS columns (Miltenyi Biotec, Bergisch-Gladbach, Germany). A mixed chimerism was defined as the presence of at least 5% recipient DNA.The standard criteria were used for grading of acute and chronic GVHD.24 Chronic GVHD was evaluated in patients who survived at least 100 days with sustained engraftment. The secondary objective was to evaluate the response rate. Response to treatment was defined according to the European Group for Blood and Marrow Transplantation/International Bone Marrow Transplantation Registry (IBMTR) criteria.25 Briefly, complete remission (CR) required a disappearance of monoclonal gammopathy in serum and urine as determined by immunofixation analysis for at least 6 weeks and less than 5% plasma cells in a bone marrow aspirate. A partial remission (PR) was defined as more than 50% reduction and a minor response (MR) as more than 25% reduction of the paraprotein level, respectively. No change (NC) was defined as a less than 25% decrease or increase of the paraprotein. Relapse was defined as recurrence of the monoclonal protein or bone marrow plasmocytosis in case of prior CR. Progression of non-CR patients required at least a 25% increase of paraprotein or development of new bone lesions. Statistical methods Survival curves for disease-free survival and overall survival were estimated by the Kaplan-Meier method. The log-rank test was performed for statistical analysis for time-dependent analyses of survival, relapse, and disease-free survival. P < .05 was considered significant. Overall survival was calculated from transplantation until death from any cause. Progression-free survival was calculated from transplantation until progression or death from any cause.
Toxicity The major toxicity according to the Bearman scale was mucositis grade I in 24% and grade II in 64% of the patients. Liver toxicity grade I/II was observed in 35% of the patients and resolved completely in all cases. No veno-occlusive disease was observed. Two patients developed grade II lung toxicity that resolved completely after steroid treatment. Because this lung toxicity might be attributed to fludarabine, the dose of fludarabine was reduced to 3 × 30 mg/m2 and subsequently no further lung toxicity was observed. Two renal failures were observed. In one patient renal function recovered completely and the other patient (no. 21) with progressive Bence Jones proteinuria died from severe GVHD. One patient (no. 7) developed fever and enlarged para-aortal lymph nodes. Due to a high Epstein-Barr virus (EBV) load as determined by PCR, anti-CD20 treatment was initiated. Two weeks after therapy he died on day 119 after unexpected sudden cardiac arrest in CR. No autopsy was performed. Positive CMV antigenemia by pp65 test was observed in 3 patients (14%), and 2 of them were treated successfully with ganciclovir. One patient with CMV seropositivity and a negative donor showed repeated CMV antigenemia and was treated with a combination of ganciclovir and foscarnet sodium. No CMV disease was noted. Two patients died of severe acute GVHD; 1 of these had Bence Jones proteinuria and renal failure; 2 patients had infections (septicemia and cerebral aspergillosis). The estimated probability of NRM was 10% at day 100 (95% CI, 1%-19%) and 26% at 1 year (95% CI, 7%-45%).Engraftment The median transplanted CD34+ cell number was 3.9 × 106/kg body weight (range, 0.4-12.5 × 106/kg body weight). All patients became neutropenic (< 0.2 × 109/L) and thrombocytopenic (< 20 × 109/L) and required platelet and erythrocyte transfusions. No primary or secondary graft failure was observed. The median time until leukocyte (> 1 × 109/L) and platelet (> 20 × 109/L) engraftment was 16 days (range, 10-24 days) and 22 days (range, 11-36 days), respectively.Chimerism Complete donor chimerism was detected in all patients by day 40. T-cell chimerism was evaluated in 11 patients and all showed complete donor chimerism on day 40 after allogeneic transplantation.GVHD Five patients (24%) did not show any signs of acute GVHD. Eight patients (38%) developed mild acute GVHD grade I; grade II was noted in 4 patients (19%). Grade II to IV acute GVHD was seen in 8 patients (38%), and severe grade III/IV GVHD was observed in 4 patients (19%). Two cases of lethal grade IV GVHD were seen, 1 in a patient with HLA-mismatched transplantation and the other in a patient with refractory disease.Chronic GVHD was evaluated in 16 patients. Ten (63%) did not show any sign of chronic GVHD. Six patients developed chronic GVHD (37%); 4 patients had limited (25%) and only 2 patients had extensive (12%) chronic GVHD. Response After allogeneic transplantation, 8 patients achieved a CR (40%) and 10 patients a PR (50%), resulting in an overall response rate of 90%. Two of the patients with a PR were only positive in immunofixation and an additional 4 patients show an ongoing decrease of monoclonal bands. One patient (5%) achieved only a MR and 1 patient progressed after allogeneic transplantation (5%). Six patients with PR prior to transplantation converted to CR after allografting. For 8 patients with PD prior to transplantation, 1 converted to CR, 6 to PR, and 1 remained progressive after unrelated allografting (Table 2). So far, 4 patients have received donor lymphocyte infusions because of progressive (n = 3) or persistent disease (n = 1). One patient developed grade II acute GVHD and showed a MR; another patient showed neither a sign of GVHD nor of tumor reduction. It is too early to evaluate 2 patients.
Overall survival and disease-free survival After a median follow-up of 386 days (range, 100-769 days), the 2-year estimated overall survival was 74% (95% CI, 54%-94%; Figure 1). In an univariate analysis there was a trend for better overall survival for patients without relapse after autologous transplantation: 86% (95% CI, 63%-99%) versus 64% (95% CI, 39%-89%; P = .3). Further univariate analysis for overall survival did not show significant difference for age (< or > 50 years), 2-microglobulin, donor sex,
remission status for prior allograft (PR/CR versus NC/MR/PD), CMV
seropositivity, time to transplantation from diagnosis, stem cell
source, acute and chronic GVHD, and CD34 cell dose. The 2-year
estimated disease-free survival was 53% (95% CI, 29%-87%). In
a univariate analysis only relapse after autologous
transplantation resulted in a less favorable outcome in comparison to
patients without relapse: 26% (95% CI, 3%-49%) versus 86% (95%
CI, 63%-99%; P = .04; Figures
2 and
3).
This study in patients with advanced MM demonstrates that a
dose-reduced conditioning regimen with allogeneic SCT from unrelated donors is a feasible and highly effective treatment. The 2-year estimated overall survival of 74% and the disease-free survival of
53% is encouraging. However, it will require a longer follow-up period
to determine the curative potential of this approach for this otherwise
fatal disease. Only a few reports exist on the outcome of unrelated SCT
in MM. In the largest report of the NMDP, 71 patients received an
unrelated stem cell transplant after standard conditioning. A day 100 mortality rate of 41% and an estimated 5-year overall survival rate of
only 17% were reported.11 Bensinger et al reported a 64%
treatment-related mortality in 14 patients who received transplants
from unrelated or mismatched related donors.12 To reduce
treatment-related mortality after allogeneic SCT, reduced-intensity
regimens based on TBI/fludarabine, busulfan/fludarabine, or
melphalan/fludarabine for related and unrelated SCT have been developed.13-18 However, in unrelated SCT, GVHD and
treatment-related mortality remain major problems. Giralt et al
reported a day 100 mortality rate of 53% and a risk of grade II to IV
acute GVHD of 62% after a melphalan/purine analog-containing
reduced-intensity regimen.17 Recently, Badros et al
reported data on 6 patients with advanced MM who received transplants
from unrelated donors after a reduced-intensity regimen consisting of
melphalan/fludarabine and low-dose TBI (2.5 Gy). They reported a day
100 mortality rate of 33% and one primary graft failure was
observed.26 In our study no graft failure occurred; only
38% of the patients developed acute stage II to IV GVHD and the
estimated NRM at day 100 was only 10% (Figure
4).
One might ask why such differences occurred with nearly the same melphalan/fludarabine-based regimen. The major difference in the studies mentioned above is the incorporation of ATG into the conditioning regimen in our study. A similar incidence of acute grade II to IV GVHD (43%) was reported for dose-reduced conditioning followed by unrelated SCT by Nagler et al, who also used ATG as part of the conditioning regimen consisting of busulfan and fludarabine.27 The ATG used in both studies was from rabbits (Fresenius-ATG). This in vivo depletion of activated T cells in the recipient might facilitate engraftment, and due to the long half-life of the immunoglobulin, an additional in vivo T-cell depletion of the graft might reduce the incidence of GVHD. Therefore, ATG as part of the conditioning regimen has been used successfully in unrelated SCT to ensure engraftment and to reduce the incidence of severe GVHD.18-21 The major concern of any form of T-cell depletion is the high incidence of relapse.28 Attempts to overcome this high incidence of relapse by donor lymphocyte infusions were associated with a high incidence of acute and chronic GVHD.29,30 In contrast to other forms of T-cell depletion or other ATG preparations, the ATG used in our study does not lead to a significant increase of relapse in unrelated and related SCT.31-33 Besides the ATG, other forms of serotherapy have been described in allogeneic SCT. Recently, stable engraftment after a dose-reduced melphalan/fludarabine regimen incorporating pretransplantation alemtuzumab (CAMPATH 1H), a humanized anti-CD52 antibody, has been described.34 In that study only 21% of the patients developed grade II to IV acute GVHD, but after donor lymphocyte infusion, which was given to 6 patients mainly to enhance remission status or donor chimerism, 50% developed grade II/III acute GVHD. Previous studies of allografting from related donors after standard
conditioning clearly showed that early transplantation in the course of
disease improves outcome.1,2,12 In our study, we
demonstrated that there was a significant better progression-free survival for those patients who received a transplant without prior
failure of autologous transplantation. Other factors such as age, time
to transplantation, response prior to transplantation, or
We thank the staff of the Bone Marrow Transplantation units for providing excellent care of our patients and the medical technicians for their excellent work in the Bone Marrow Transplantation laboratories.
Submitted April 16, 2002; accepted July 3, 2002.
Prepublished online as Blood First Edition Paper, August 8, 2002; DOI 10.1182/blood-2002-04-1150.
Supported by a grant from the Roggenbuck-Stiftung.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Nicolaus Kröger, The Department of Bone Marrow Transplantation, University Hospital Hamburg-Eppendorf, Martinistr 52, D-20246 Hamburg, Germany; e-mail: nkroeger{at}uke.uni-hamburg.de.
1. Gahrton G, Tura S, Ljungman P, et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol. 1995;13:1312-1322[Abstract]. 2. Cavo M, Benni M, Cirio TM, et al. Allogeneic bone marrow transplantation for the treatment of multiple myeloma: an overview of published reports. Stem Cells. 1995;13:126-131.
3.
Martinelli G, Terragna C, Zamagni E, et al.
Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma.
J Clin Oncol.
2000;18:2273-2281
4.
Corradini P, Voena C, Tarella C, et al.
Molecular and clinical remission in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells.
J Clin Oncol.
1999;17:208-215
5.
Björkstrand B, Ljungman P, Svensson H, et al.
Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case matched study from the European Group for Blood and Marrow Transplantation.
Blood.
1996;88:4711-4718
6.
Lokhorst HM, Schattenberg A, Cornelissen JJ, et al.
Donor lymphocyte infusion for relapsed multiple myeloma after allogeneic stem cell transplantation: predictive factors for response and long term outcome.
J Clin Oncol.
2000;18:3031-3037
7.
Tricot G, Vesole DH, Jagannath S, et al.
Graft versus myeloma effect: proof of a principle.
Blood.
1996;87:1196-1198 8. Majolino I, Corradini P, Scime R, et al. Allogeneic transplantation of unmanipulated peripheral blood stem cells in patients with multiple myeloma. Bone Marrow Transplant. 1998;22:449-455[CrossRef][Medline] [Order article via Infotrieve]. 9. Gahrton G, Svenson H, Cavo M, et al. Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres. Br J Haematol. 2001;113:209-216[CrossRef][Medline] [Order article via Infotrieve].
10.
Weisdorf DJ, Anasetti C, Antin JH, et al.
Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation.
Blood.
2002;99:1971-1977 11. Ballen K, King R, Carston M, et al. Outcome of unrelated transplants in patients with multiple myeloma [abstract]. Blood. 2000;96(suppl 1):1780.
12.
Bensinger WI, Buckner CD, Anasetti C, et al.
Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome.
Blood.
1996;88:2787-2793
13.
Giralt S, Estey E, Albitar M, et al.
Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft versus leukemia effect without myeloablative therapy.
Blood.
1997;89:4531-4536
14.
Slavin S, Nagler A, Naperstek E, et al.
Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant diseases.
Blood.
1998;91:756-763
15.
McSweeney P, Niederwieser D, Shizuru JA, et al.
Hematopoietic cell transplantation in older patients with hematological malignancies: replacing high-dose cytotoxic therapy with graft versus tumor effects.
Blood.
2001;97:3390-3400 16. Giralt S, Weber D, Cohen A, et al. Non-myeloablative conditioning with fludarabine, melphalan, for patients with multiple myeloma (MM) [abstract]. Proc Am Soc Clin Oncol. 1999;18:6a.
17.
Giralt S, Thall PF, Issa K, et al.
Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation.
Blood.
2001;97:631-637 18. Kröger N, Zabelina T, Krüger W, et al. Anti-thymocyte-globulin as part of the preparative regimen prevents acute and chronic graft versus host disease (GvHD) in allogeneic stem cell transplantation from unrelated donors. Ann Haematol. 2001;80:209-215[CrossRef][Medline] [Order article via Infotrieve]. 19. Finke J, Bertz H, Schmoor C, et al. Allogeneic bone marrow transplantation from unrelated donors using in vivo anti T-cell globulin. Br J Haematol. 2000;11:303-313. 20. Zander AR, Zabelina T, Kröger N, et al. Use of a five-agent GvHD prevention regimen in recipients of unrelated donor marrow. Bone Marrow Transplant 1999;23:889-893[CrossRef][Medline] [Order article via Infotrieve]. 21. Kolb HJ, Holler E, Knabe H, et al. Conditioning treatment with antithymocyte globulin (ATG) modifies graft-vs-host disease in recipients of marrow from unrelated donors [abstract]. Blood. 1995;86(suppl 1):952a.
22.
Kröger N, Schwerdtfeger R, Kiehl M, et al.
Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rates in multiple myeloma.
Blood.
2002;100:755-760
23.
Bearman SI, Appelbaum FR, Buckner CD, et al.
Regimen related toxicity in patients undergoing bone marrow transplantation.
J Clin Oncol.
1988;6:1562-1568 24. Przepiorka KM, Weisdorf D, Martin P. 1994 Consensus Conference on acute GvHD-grading. Bone Marrow Transplant. 1995;15:825-828[Medline] [Order article via Infotrieve]. 25. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. Br J Haematol. 1998;120:1115-1123.
26.
Badros A, Barlogie B, Siegel E, et al.
Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning.
J Clin Oncol.
2002;20:1295-1303 27. Nagler A, Aker M, Or R, et al. Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation. Exp Hematol. 2001;29:362-370[CrossRef][Medline] [Order article via Infotrieve].
28.
Marmont A, Horowitz M, Gale R, et al.
T-cell depletion of HLA-identical transplants in leukemia.
Blood.
1991;78:2120-2130 29. Naparstek E, Or R, Nagler A, et al. T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using CAMPATH-1 antibodies and post transplant administration of donors peripheral blood lymphocytes for prevention of relapse. Br J Haematol. 1995;89:506-515[Medline] [Order article via Infotrieve]. 30. Barrett A, Mavroudis D, Tisdale J, et al. T-cell depleted bone marrow transplantation and delayed T-cell add-back to control acute GvHD and conserve a graft versus leukemia effect. Bone Marrow Transplant. 1998;21:543-551[CrossRef][Medline] [Order article via Infotrieve]. 31. Kröger N, Zabelina T, Krüger W, et al. In-vivo T-cell depletion with pretransplant anti-thymocyte globulin reduces graft versus host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors. Bone Marrow Transplant. 2002;29:683-689[CrossRef][Medline] [Order article via Infotrieve]. 32. Zander AR, Kröger N, Finke J, et al. GvH-prophylaxis with antithymocyte globuline in recipients of matched unrelated donor transplants for chronic myelogenous leukemia: a retrospective analysis. Bone Marrow Transplant. 2001;27(suppl 1):494. 33. Remberger M, Svahn BM, Hentschke P, et al. Effect on cytokine release, engraftment and GvHD of different anti T-cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation. Bone Marrow Transplant. 1999;23(suppl 1):268.
34.
Chakraverty R, Peggs K, Chopra R, et al.
Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen.
Blood.
2002;99:1071-1078
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  J. El-Cheikh, M. Michallet, A. Nagler, H. de Lavallade, F. E. Nicolini, A. Shimoni, C. Faucher, M. Sobh, D. Revesz, I. Hardan, et al. High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma Haematologica, March 1, 2008; 93(3): 455 - 458. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Barlogie, R. A. Kyle, K. C. Anderson, P. R. Greipp, H. M. Lazarus, D. D. Hurd, J. McCoy, S. R. Dakhil, K. S. Lanier, R. A. Chapman, et al. Standard Chemotherapy Compared With High-Dose Chemoradiotherapy for Multiple Myeloma: Final Results of Phase III US Intergroup Trial S9321 J. Clin. Oncol., February 20, 2006; 24(6): 929 - 936. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Geffroy-Luseau, A. Moreau-Aubry, R. Bataille, and C. Pellat-Deceunynck Allogeneic T lymphocytes as a source of peptide-dependent T cells specific for myeloma cells Int. Immunol., September 1, 2005; 17(9): 1193 - 1200. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Crawley, M. Lalancette, R. Szydlo, M. Gilleece, K. Peggs, S. Mackinnon, G. Juliusson, L. Ahlberg, A. Nagler, A. Shimoni, et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT Blood, June 1, 2005; 105(11): 4532 - 4539. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Kroger, A. Shimoni, M. Zagrivnaja, F. Ayuk, M. Lioznov, H. Schieder, H. Renges, B. Fehse, T. Zabelina, A. Nagler, et al. Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma Blood, November 15, 2004; 104(10): 3361 - 3363. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Kroger, G. Schilling, H. Einsele, P. Liebisch, A. Shimoni, A. Nagler, J. A. Perez-Simon, J. F. San Miguel, M. Kiehl, A. Fauser, et al. Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation Blood, June 1, 2004; 103(11): 4056 - 4061. [Abstract] [Full Text] [PDF]
|
|
Top
Abstract
Introduction
donors.
